Pharmaceutical Technology: Controlled Drug Release, Volume 2

More documents

Recommendations

Info

IMPLANTS [CH. 17 187 Table 2—Results of fitting parameters a, and n of equation (2) or parameters l, and m of equation (3) to release data of matrices containing HEC or BSA Results are not given if fits were not possible. Inferior results are given in parentheses. Fig. 1—Gly-Tyr release from PDMS matrices containing HEC (viscosity grade 300 mPas) matrix loadings (w/w): ▲, 30%; ▼, 35%; ♦, 40%, ■. 50%. , —fit of equation (2); , ---fit of equation (3). Mean values, n=3. RELEASE MECHANISM The results show, that release profiles never followed a t 1/2 law (equation (1)). A marked influence of the excipient’s viscosity grade or dissolution rate on drug release is further observed. The swelling profiles for matrices containing low-viscosity HEC or BSA are shown in Figs 4–6. The profiles show that maximum swelling is always observed in cases of quick drug depletion and bent
188 CH. 17] SILICON MATRIX SYSTEMS FOR LONG-TERM CONSTANT RELEASE OF PEPTIDES Fig. 2—Gly-Tyr release from PDMS matrices containing HEC (matrix loading 30% (w/w)). Viscosity grades of excipient were 300 (●), 6000 (∆), and 30000 (▲) mPas. —, fit of equation (2). Mean values, n=3. Fig. 3—Gly-Tyr release from PDMS matrices containing BSA. Quickly dissolving BSA: matrix loadings (w/w) of 40% (●) and 50%) . Slowly dissolving BSA: Slowly dissolving BSA: loadings (w/w) of 30% (▲), 40% (♦), and 50% .Fits of equation (2) (—) and equation (3) (---) are shown. Mean values, n=3. release cures. Only in cases where maxima of swelling profiles are not observed do the corresponding release profiles show a reduced decline of release rates. The results further show that for the quickly dissolving excipient (HEC) low matrix loading is a prerequisite for fitting equation (1) and getting release exponents greater than 0.5. For slowly dissolving BSA, however, reduced decline or release rates may also be obtained at high loading levels up to 50% (w/w). Finally, a gravimetric assay of matrices shows that the residence time of excipient is markedly prolonged if matrix loading is low or if the dissolution rate of excipient is reduced (Table 3).
Page 2 and 3:
PHARMACEUTICAL TECHNOLOGY Controlle
Page 4 and 5:
3 TABLET MACHINE INSTRUMENTATION IN
Page 6 and 7:
First published in 1991 by ELLIS HO
Page 8 and 9:
7 10 Controlled delivery of theophy
Page 10:
Slow and steady wins the race Poems
Page 14 and 15:
1 Influence of drug solubility in t
Page 16 and 17:
CH. 1] INFLUENCE OF DRUG SOLUBILITY
Page 18 and 19:
Page 20 and 21:
Page 22:
Page 25 and 26:
24 MATRIX FORMULATIONS [CH. 2 MATER
Page 27 and 28:
26 MATRIX FORMULATIONS [CH. 2 Fig.
Page 29 and 30:
28 MATRIX FORMULATIONS [CH. 2 Table
Page 31 and 32:
30 MATRIX FORMULATIONS [CH. 2 The e
Page 33 and 34:
Page 35 and 36:
34 CH. 3] THE FORMULATION OF SUSTAI
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 44 and 45:
4 Statistical optimization of a con
Page 46 and 47:
MATRIX FORMULATIONS [CH. 4 45 (4) G
Page 48 and 49:
MATRIX FORMULATIONS [CH. 4 47 Fig.
Page 50 and 51:
Columns 1-4 lead to the matrix of e
Page 52 and 53:
MATRIX FORMULATIONS [CH. 4 51 Table
Page 54 and 55:
MATRIX FORMULATIONS [CH. 4 53 Fig.
Page 56:
Fig. 5—Linearization of the relea
Page 59 and 60:
58 MATRIX FORMULATIONS [CH. 5 Pevik
Page 61 and 62:
60 MATRIX FORMULATIONS [CH. 5 The d
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 72 and 73:
6 Controlled release matrix tablets
Page 74 and 75:
CH. 6] CONTROLLED RELEASE MATRIX TA
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
7 A new ibuprofen pulsed release or
Page 82 and 83:
CH. 7] A NEW IBUPROFEN PULSED RELEA
Page 84 and 85:
Page 86 and 87:
Page 88:
Page 91 and 92:
90 CH. 8] TOPICAL RELEASE AND PERME
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
100
Page 103 and 104:
102
Page 105 and 106:
104 MULTIPARTICULATES [CH. 9 parace
Page 107 and 108:
106 MULTIPARTICULATES [CH. 9 (a) th
Page 109 and 110:
108 MULTIPARTICULATES [CH. 9 Fig. 2
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
116
Page 119 and 120:
118 CH. 10] CONTROLLED DELIVERY OF
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
126 CH. 11] THE EFFECT OF FOOD ON G
Page 129 and 130:
128 CH. 11] THE EFFECT OF FOOD ON G
Page 131 and 132:
130
Page 133 and 134:
132 CH. 12] BIODEGRADABLE POLYMERS
Page 135 and 136:
134 CH. 12] BIODEGRADABLE POLYMERS
Page 137 and 138: 136 CH. 12] BIODEGRADABLE POLYMERS
Page 139 and 140: 138 CH. 12] BIODEGRADABLE POLYMERS
Page 141 and 142: 140
Page 143 and 144: 142 CH. 13] A COMPARISON OF DISSOLU
Page 153 and 154: 152
Page 155 and 156: 154
Page 157 and 158: 156 OPHTHALMIC FORMULATION [CH. 14
Page 163 and 164: 162 CH. 15] A SUSTAINED RELEASE OPH
Page 171 and 172: 170
Page 173 and 174: 172 IMPLANTS [CH. 16 The purpose of
Page 175 and 176: 174 IMPLANTS [CH. 16 times with 5 m
Page 177 and 178: 176 IMPLANTS [CH. 16 noted that the
Page 179 and 180: 178 IMPLANTS [CH. 16 Fig. 1—The e
Page 181 and 182: 180 IMPLANTS [CH. 16 Table 3—Tobr
Page 183 and 184: 182
Page 185 and 186: 184 CH. 17] SILICON MATRIX SYSTEMS
Page 187: 186 CH. 17] SILICON MATRIX SYSTEMS
Page 191 and 192: 190 CH. 17] SILICON MATRIX SYSTEMS
Page 193 and 194: 192
Page 195 and 196: 194 INDEX dry granulation, 43 elect
show all

Pharmaceutical Technology: Controlled Drug Release, Volume 2

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?